Resources

Understanding levels of immunocompromise in children and adults with HIV.

Zoster vaccine (Zostavax) screening for contraindications

Various Lyssavirus exposure categories from no exposure to severe exposure, description and recommended post-exposure prophylaxis management.

Minimum acceptable age for the 1st dose of scheduled NIP-funded vaccines in infants and action/s to be undertaken if a vaccine dose is inadvertently given before the recommended minimum age.

Minimum acceptable dose intervals for children <10 years of age which are only to be used for catch-up vaccination.

Monovalent hepatitis B vaccines by age of vaccine recipient in years, showing dose, number of doses, recommended minimum intervals between doses, and alternative schedule minimum intervals.

Table showing the the number of vaccine doses a child should have received by their current age. This table should be used to work up a catch-up schedule for the child.

Post-exposure prophylaxis for non-immune people exposed to a source that is positive for hepatitis B surface antigen based on the type of exposure and guidance for the use of the Hep B immunoglobulin.

Post-exposure prophylaxis needed within 72 hours of 1st exposure for people exposed to measles based on age or immune status and MMR doses had to date, if any.

A checklist for immunisation providers to use to decide about vaccinating a person.

Protective neutralising antibody levels for JEspect in vaccinated people in Europe based on the region and duration since vaccination.

List of rabies vaccines available globally, and their compatibility with vaccines registered in Australia

Signs to recognise, management and treatment of anaphylaxis including adrenaline dosage based on the person's age if the exact weight of the person is not known.

Recommendations for immunisation of healthy people without any medical conditions associated with increased risk of invasive meningococcal disease, aged less than 2 years using meningococcal ACWY vaccines, by age at the start of the course and vaccine brand

Recommendations for immunisation of infants and children aged <2 years using meningococcal B vaccine by age at start of vaccine course, vaccine brand and dose requirements for healthy people (without any medical conditions associated with increased risk of invasive meningococcal disease).